Sec Form 3 Filing - Nau Jeffrey @ Oyster Point Pharma, Inc. - 2019-10-30

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Nau Jeffrey 2. Issuer Name and Ticker or Trading Symbol Oyster Point Pharma, Inc. [ OYST] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) President and CEO (Last) (First) (Middle) C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109 3. Date of Earliest Transaction (MM/DD/YY) 10/30/2019 (Street) PRINCETON, NJ08540 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 0.2 ( 1 ) 05/24/2027 Common Stock, par value $0.001 per share 11,031 D Employee Stock Option (Right to Buy) $ 1.02 ( 2 ) 11/10/2027 Common Stock, par value $0.001 per share 519,774 D Employee Stock Option (Right to Buy) $ 5.33 ( 3 ) 06/06/2029 Common Stock, par value $0.001 per share 309,721 D Employee Stock Option (Right to Buy) $ 5.33 ( 4 ) 06/06/2029 Common Stock, par value $0.001 per share 77,430 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Nau Jeffrey C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON, NJ08540 X President and CEO Signatures /s/Jeffrey Nau 10/30/2019 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Option granted on May 24, 2017 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan (the "Plan"). All of the common stock, $0.001 par value per share (the "Common Stock"), of the Issuer subject to the option vested on September 25, 2017. ( 2 )Option granted on November 10, 2017 under the Plan. One forty-eighth of the total number of shares subject to the option vested on December 1, 2017, and one forty-eighth of the remaining shares vested, and continue to vest, monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances. ( 3 )Option granted on June 6, 2019 under the Plan. One forty-eighth of the total number of shares subject to the option vested on June 3, 2019, and one forty-eighth of the remaining shares vested, and continue to vest, monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances. ( 4 )Option granted on June 6, 2019 under the Plan. All of the Common Stock of the Issuer subject to the option vested on July 24, 2019.

Remarks: Exhibit 24 - Power of Attorney

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.